The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...

DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced third quarter 2025 results on November 12th, 2025, and held a conference call to discuss them after ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

One person’s side effect could be another person’s treatment if we expand our perspective on small molecule drug targets, ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

CompletedstrategicpivotfromR&Dfocustocommercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website ...

Ecuadorian scientists have, for the first time, edited the gene of a fungus that destroys banana plantations. Using an ...

Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol ...

Using genomics, evolutionary biologists test several hypotheses on the origin of viruses. New evidence suggests they may have ...

Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology ...